Alembic Pharma invests in RIGImmune
Advertisement
Mumbai: Alembic Pharmaceuticals Limited has recently announced that the company has made a strategic investment in RIGImmune Inc., a biopharmaceutical research company co-founded by two prominent Yale University professors.
RIGImmune Inc. was founded by Dr. Anna Pyle and Dr. Akiko Iwasaki. Dr. Pyle is a Professor of Molecular, Cellular and Developmental Biology at Yale University and an investigator for the Howard Hughes Medical Institute. She is a pioneer in the field of RNA biochemistry. Dr. Akiko Iwasaki is a Professor in the Department of Immunology and a Professor of Molecular, Cellular, and Developmental Biology at Yale University. She is also an investigator for the Howard Hughes Medical Institute and a pioneer in the field of immunology.
RIGImmune, Inc. is focused on the development of RNA based therapies for viral diseases and oncology applications by targeting the innate immune target, RIG-I. RIGImmune will utilize the proceeds of the series seed round to further the development of therapeutic oligonucleotides developed by Dr. Pyle and Dr. Iwasaki.
Alembic has acquired preferred stock in RIGImmune amounting to a 19.97% post- money stake in the first closing of the series seed round that was completed recently.
On this occasion, Mr. Pranav Amin, MD of Alembic stated: "We are very excited to make this investment in RIGImmune Inc., a company founded by two of the world's leading scientists in innate immunity and RNA based therapies. Alembic believes in bringing differentiated and innovative products to help address unmet needs. Apart from pursuing internal projects, we believe we can accelerate our efforts by making strategic investments in companies that are leaders in their field and this investment marks the beginning for us. We wish to thank Dr. Pyle, Dr. Iwasaki, and the management team of RIGImmune Inc. and assure them of our support in bringing these innovations to patients".
"We are delighted to have Alembic, a global pharmaceutical development firm, as a major participant in the seed financing round for RIGImmune," said Martin Driscoll, Chairman of the Board of Directors for RIGImmune. "We look forward to working with the Alembic team as we advance our novel stem loop RNA therapeutics as potential treatments for patients suffering from viral diseases and cancer".
Read also: Alembic Pharma Selexipag bags USFDA okay
Our comments section is governed by our Comments Policy . By posting comments at Medical Dialogues you automatically agree with our Comments Policy , Terms And Conditions and Privacy Policy .
Disclaimer: This website is primarily for healthcare professionals. The content here does not replace medical advice and should not be used as medical, diagnostic, endorsement, treatment, or prescription advice. Medical science evolves rapidly, and we strive to keep our information current. If you find any discrepancies, please contact us at corrections@medicaldialogues.in. Read our Correction Policy here. Nothing here should be used as a substitute for medical advice, diagnosis, or treatment. We do not endorse any healthcare advice that contradicts a physician's guidance. Use of this site is subject to our Terms of Use, Privacy Policy, and Advertisement Policy. For more details, read our Full Disclaimer here.
NOTE: Join us in combating medical misinformation. If you encounter a questionable health, medical, or medical education claim, email us at factcheck@medicaldialogues.in for evaluation.